BKZ showed clinically meaningful improvements in efficacy outcomes in bDMARD-naïve PsA pts at Wk 16 through wk 52. No new safety signals. ABS L02 #ACR22 @RheumNow https://t.co/Dph32O7NWG https://t.co/d7Yq3JISyF
Links:
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Ar…
http://ow.ly/UtqS50LpH6W
14-11-2022